FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800549314> ?p ?o ?g. }

• W2800549314 endingPage "223" @default.
• W2800549314 startingPage "223" @default.
• W2800549314 abstract "Decreased trough levels of infliximab (TLI) and antibodies to infliximab (ATI) are associated with loss of response (LOR) in Crohn's disease. Two prospective studies were conducted to determine whether TLI or ATI better correlates with LOR (Study 1), and whether TLI could become a predictor of mucosal healing (MH) (Study 2).Study 1 was conducted in 108 patients, including those with LOR and remission to compare ATI and TLI in discriminating the 2 conditions based on receiver operating characteristic (ROC) curve analyses. Study 2 involved 35 patients who were evaluated endoscopically.In Study 1, there were no differences between the 2 assays in ROC curve analyses; the TLI cutoff value for LOR was 2.6 µg/mL (sensitivity, 70.9%; specificity, 79.2%), and the ATI cutoff value was 4.9 µg/mL (sensitivity, 65.5%; specificity, 67.9%). The AUROC (area under the ROC curve) of TLI was greater than that of ATI. AUROC was useful for discriminating between the 2 conditions. In Study 2, the TLI was significantly higher in the colonic MH group than in the non-MH group (2.7 µg/mL vs. 0.5 µg/mL, P=0.032).TLI is better than ATI for clinically diagnosing LOR, and a correlation was observed between TLI and colonic MH." @default.
• W2800549314 created "2018-05-17" @default.
• W2800549314 creator A5001105075 @default.
• W2800549314 creator A5004508919 @default.
• W2800549314 creator A5008181587 @default.
• W2800549314 creator A5010809759 @default.
• W2800549314 creator A5012308003 @default.
• W2800549314 creator A5014227547 @default.
• W2800549314 creator A5025671560 @default.
• W2800549314 creator A5029745803 @default.
• W2800549314 creator A5032480442 @default.
• W2800549314 creator A5037324336 @default.
• W2800549314 creator A5043318905 @default.
• W2800549314 creator A5047842545 @default.
• W2800549314 creator A5071443972 @default.
• W2800549314 creator A5074219274 @default.
• W2800549314 creator A5075152783 @default.
• W2800549314 creator A5082172710 @default.
• W2800549314 date "2018-01-01" @default.
• W2800549314 modified "2023-10-01" @default.
• W2800549314 title "Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study" @default.
• W2800549314 cites W1498083162 @default.
• W2800549314 cites W1515981258 @default.
• W2800549314 cites W1996472975 @default.
• W2800549314 cites W2003949246 @default.
• W2800549314 cites W2020350753 @default.
• W2800549314 cites W2032346246 @default.
• W2800549314 cites W2043261411 @default.
• W2800549314 cites W2072640801 @default.
• W2800549314 cites W2072806283 @default.
• W2800549314 cites W2076918309 @default.
• W2800549314 cites W2087663450 @default.
• W2800549314 cites W2106072130 @default.
• W2800549314 cites W2126568228 @default.
• W2800549314 cites W2136589391 @default.
• W2800549314 cites W2153438195 @default.
• W2800549314 cites W2171341132 @default.
• W2800549314 cites W2195373199 @default.
• W2800549314 cites W2340680662 @default.
• W2800549314 cites W3149527659 @default.
• W2800549314 doi "https://doi.org/10.5217/ir.2018.16.2.223" @default.
• W2800549314 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5934595" @default.
• W2800549314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29743835" @default.
• W2800549314 hasPublicationYear "2018" @default.
• W2800549314 type Work @default.
• W2800549314 sameAs 2800549314 @default.
• W2800549314 citedByCount "10" @default.
• W2800549314 countsByYear W28005493142019 @default.
• W2800549314 countsByYear W28005493142020 @default.
• W2800549314 countsByYear W28005493142021 @default.
• W2800549314 crossrefType "journal-article" @default.
• W2800549314 hasAuthorship W2800549314A5001105075 @default.
• W2800549314 hasAuthorship W2800549314A5004508919 @default.
• W2800549314 hasAuthorship W2800549314A5008181587 @default.
• W2800549314 hasAuthorship W2800549314A5010809759 @default.
• W2800549314 hasAuthorship W2800549314A5012308003 @default.
• W2800549314 hasAuthorship W2800549314A5014227547 @default.
• W2800549314 hasAuthorship W2800549314A5025671560 @default.
• W2800549314 hasAuthorship W2800549314A5029745803 @default.
• W2800549314 hasAuthorship W2800549314A5032480442 @default.
• W2800549314 hasAuthorship W2800549314A5037324336 @default.
• W2800549314 hasAuthorship W2800549314A5043318905 @default.
• W2800549314 hasAuthorship W2800549314A5047842545 @default.
• W2800549314 hasAuthorship W2800549314A5071443972 @default.
• W2800549314 hasAuthorship W2800549314A5074219274 @default.
• W2800549314 hasAuthorship W2800549314A5075152783 @default.
• W2800549314 hasAuthorship W2800549314A5082172710 @default.
• W2800549314 hasBestOaLocation W28005493141 @default.
• W2800549314 hasConcept C112705442 @default.
• W2800549314 hasConcept C121332964 @default.
• W2800549314 hasConcept C126322002 @default.
• W2800549314 hasConcept C188816634 @default.
• W2800549314 hasConcept C198433322 @default.
• W2800549314 hasConcept C2777138892 @default.
• W2800549314 hasConcept C2778217198 @default.
• W2800549314 hasConcept C2779134260 @default.
• W2800549314 hasConcept C2779280984 @default.
• W2800549314 hasConcept C3020225094 @default.
• W2800549314 hasConcept C58471807 @default.
• W2800549314 hasConcept C62520636 @default.
• W2800549314 hasConcept C71924100 @default.
• W2800549314 hasConcept C76318530 @default.
• W2800549314 hasConcept C90924648 @default.
• W2800549314 hasConceptScore W2800549314C112705442 @default.
• W2800549314 hasConceptScore W2800549314C121332964 @default.
• W2800549314 hasConceptScore W2800549314C126322002 @default.
• W2800549314 hasConceptScore W2800549314C188816634 @default.
• W2800549314 hasConceptScore W2800549314C198433322 @default.
• W2800549314 hasConceptScore W2800549314C2777138892 @default.
• W2800549314 hasConceptScore W2800549314C2778217198 @default.
• W2800549314 hasConceptScore W2800549314C2779134260 @default.
• W2800549314 hasConceptScore W2800549314C2779280984 @default.
• W2800549314 hasConceptScore W2800549314C3020225094 @default.
• W2800549314 hasConceptScore W2800549314C58471807 @default.
• W2800549314 hasConceptScore W2800549314C62520636 @default.
• W2800549314 hasConceptScore W2800549314C71924100 @default.
• W2800549314 hasConceptScore W2800549314C76318530 @default.
• W2800549314 hasConceptScore W2800549314C90924648 @default.

• next